David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky; ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Alchemab Therapeutics enters $415 million licensing agreement with Eli Lilly for ATLX-1282: Cambridge, UK Wednesday, May 7, 2025, 12:00 Hrs [IST] Alchemab Therapeutics (Alchemab), ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Beyond GLP-1, Lilly’s $11 billion research and development investments power a diverse pipeline. Its Alzheimer’s drug Kisunla ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.